Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Breakthrough CMV Viremia Outcomes of Letermovir Prophylaxis in Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide

Arthur Nguyen, Joseph S Bubalo, Jennifer N. Saultz, Brandon Hayes-Lattin, Andy Chen, Rachel J. Cook, Arpita Gandhi, Jessica Leonard, Richard T. Maziarz, Yazan Migdady, Eneida R. Nemecek, Levanto Schachter

Blood (2022) 140 (Supplement 1): 12856–12858.

https://doi.org/10.1182/blood-2022-156011

Published: 2022

Journal Articles

FLT3-Mutated Acute Myeloid Leukemia Using a Novel Regimen of Gemtuzumab Ozogamicin and Midostaurin in Combination with Standard Cytarabine and Daunorubicin Induction Therapy

Uma Borate, Andy Kaempf, Jessica Minnier, Shikha Misra, Shaun Goodyear, Gabrielle Meyers, Jennifer N. Saultz, Elie Traer, Ronan Swords, Rachel J. Cook, Sammantha Avaylon, Melissa Mackey, Brianna Norris, Roland B. Walter

Blood (2021) 138 (Supplement 1): 1269.

https://doi.org/10.1182/blood-2021-152791

Published: 2021

Journal Articles

SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial

Blood (2021) 138 (Supplement 1): 3436.

https://doi.org/10.1182/blood-2021-150277

Published: 2021

Journal Articles

Early Infection after Allogeneic Transplant Increases NRM without Influencing Relapse Rate

Jennifer N Saultz, DO, Kaycee Moshofsky, BS, Andy Kaempf, MS, Guang Fan, MD PhD, Gabrielle Meyers, Rachel J. Cook, MD, Richard T. Maziarz, MD, Peggy Appel, Francisco Tria, MD, Staci Williamson, MS

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-142048

Published: 2020

Journal Articles

SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia

Stephane De Botton, Thomas Cluzeau, MDPhD, Carlos Enrique Vigil, MD, Rachel J. Cook, MD, Philippe Rousselot, MDPhD, David A Rizzieri, MD, Jane L. Liesveld, MD, Pierre Fenaux, MD PhD, Thorsten Braun, MD PhD, Anne Banos, MD, Michael R. Savona, MD, Don Park, MD, Michael J. Kelly, MD MPH, MS, Angela Volkert, Li Zhou, PhD, Qing Kang-Fortner, PhD, David A. Roth, MD, Eytan M. Stein, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-134600

Published: 2020

Journal Articles

Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

Eytan M. Stein, MD, Stephane De Botton, Thomas Cluzeau, MDPhD, Arnaud Pigneux, MD PhD, Jane L. Liesveld, MD, Rachel J. Cook, MD, Philippe Rousselot, MDPhD, David A Rizzieri, MD, Thorsten Braun, MD PhD, Dale L. Bixby, MD, Gail J. Roboz, MD, Delphine Lebon, MD, Mael Heiblig, Michael J. Kelly, MD MPH, MS, Angela Volkert, Li Zhou, PhD, Qing Kang-Fortner, PhD, David A. Roth, MD, Pierre Peterlin, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-134602

Published: 2020

Journal Articles

Feasibility and Cost Analysis of Day 4 Granulocyte Colony-Stimulating Factor Mobilized Peripheral Blood Progenitor Cell Collection from HLA-Matched Sibling Donors

Laura F. Newell, MD, Rebekah Knight, Kelsea Shoop, Sara Murray, Rogelyn Kwock, NP, Carol Jacoby, NP, Susan Slater, NP, Bryon Allen, NP, Brad Cota, MBA, Peggy Appel, Rachel J. Cook, MD, Richard T. Maziarz, MD, Gabrielle Meyers, MD

Blood (2018) 132 (Supplement 1): 4558.

https://doi.org/10.1182/blood-2018-99-120342

Published: 2018

Journal Articles

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Rachel J. Cook, MD, Tamara Moyo, MD PhD, Jane L. Liesveld, MD, David A. Rizzieri, MD, Eytan M. Stein, MD, Stephane De Botton, MD PhD, Gail J. Roboz, MD, Mikkael A. Sekeres, MD MS, Joseph G. Jurcic, MD, Azra Raza, MD, Robert L. Redner, MD, Dale L. Bixby, MD PhD, Jorge E. Cortes, MD, Kristin Stephens, Angela Volkert, Qing Kang, PhD, Emmanuelle Di Tomaso, PhD, David A. Roth, MD, Carlos E Vigil, MD

Blood (2018) 132 (Supplement 1): 2735.

https://doi.org/10.1182/blood-2018-99-111285

Published: 2018

Journal Articles

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment

Blood (2017) 130 (Supplement 1): 2633.

https://doi.org/10.1182/blood.V130.Suppl_1.2633.2633

Published: 2017

Journal Articles

Healthcare Consumption Amongst Older Patients with High Risk AML Treated with Hypomethylating Agents Is Similar to That of Patients Receiving Induction Chemotherapy

Curtis A Lachowiez, MD, Matthew Kearney, MD, Gabrielle Meyers, MD, Rachel J. Cook, MD

Blood (2017) 130 (Supplement 1): 2155.

https://doi.org/10.1182/blood.V130.Suppl_1.2155.2155

Published: 2017

Journal Articles

A Phase 1/2 Study of the Oral Novel JAK1 Inhibitor INCB052793 As Monotherapy and in Combination with Standard Therapies in Patients with Advanced Hematologic Malignancies

Amer M. Zeidan, MD, Rachel J. Cook, MD, Rodolfo Bordoni, MD, Ekaterine Asatiani, MD, Gongfu Zhou, Théa Faivre, Michael Byrne, MD, Michael R. Savona, MD

Blood (2017) 130 (Supplement 1): 640.

https://doi.org/10.1182/blood.V130.Suppl_1.640.640

Published: 2017

Journal Articles

Increased NKT-like Cells and Markers of T Cell Activation in Long Term Survivors of Allogeneic Hematopoietic Cell Transplantation

Shernan G. Holtan, MD, Laura Newell, MD, Rachel J Cook, MD MS, Kaitlin Pataroque, Nicky Leeborg, MD, Richard T. Maziarz, MD, Guang Fan, MD PhD

Blood (2014) 124 (21): 3958.

https://doi.org/10.1182/blood.V124.21.3958.3958

Published: 2014

Journal Articles

The Contribution of Toll-like Receptor (TLR) Pathway Hyper-Reactivity to Clonal Selection in Secondary MDS and AML

Laura F. Newell, MD, R. K. Rathbun, Michael R Garbati, PhD, Kim-Hien T. Dao, DO,PhD, Shernan G. Holtan, MD, Rachel J Cook, MD MS, Gabrielle Meyers, MD, Grover C. Bagby, MD MACP

Blood (2014) 124 (21): 4621.

https://doi.org/10.1182/blood.V124.21.4621.4621

Published: 2014

Journal Articles

The Utility Of Monitoring Chimerism: More Predictive For Nonablative Regimens?

Lyndsey Runaas, MD, Walter L. Longo, MD, Mark Juckett, MD, Wayne Borcherding, BS, Peiman Hematti, MD, Rachel J Cook, MD, MS

Blood (2013) 122 (21): 5490.

https://doi.org/10.1182/blood.V122.21.5490.5490

Published: 2013

Journal Articles

Is There a Role for ASCT in Patients with Desmoplastic Small Round Cell Tumor of the Peritoneum?

Rachel J Cook, MD, MS, Zhiwei Wang, MS, Mukta Arora, MD, Hillard M. Lazarus, MD, Kimberly A. Kasow, DO, Martin A. Champagne, MD, FRCPC, Wael Saber, MD, MS, Koen M. Van Besien, MD, Gregory A. Hale, MD, Edward A. Copelan, MD, Mohamed Elmongy, MD, DSc, Naoto T Ueno, MD, Biljana N. Horn, MD, Shimon Slavin, MD, Edward A. Stadtmauer, MD

Blood (2011) 118 (21): 3092.

https://doi.org/10.1182/blood.V118.21.3092.3092

Published: 2011

Journal Articles

Transfusion Practices of Critical Care Physicians During Shortages

Rachel J Cook, MD, MS, David Asch, M.D., MBA

Blood (2010) 116 (21): 4401.

https://doi.org/10.1182/blood.V116.21.4401.4401

Published: 2010

NARROW

Breakthrough CMV Viremia Outcomes of Letermovir Prophylaxis in Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide

FLT3-Mutated Acute Myeloid Leukemia Using a Novel Regimen of Gemtuzumab Ozogamicin and Midostaurin in Combination with Standard Cytarabine and Daunorubicin Induction Therapy

SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial

Early Infection after Allogeneic Transplant Increases NRM without Influencing Relapse Rate

SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia

Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

Feasibility and Cost Analysis of Day 4 Granulocyte Colony-Stimulating Factor Mobilized Peripheral Blood Progenitor Cell Collection from HLA-Matched Sibling Donors

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment

Healthcare Consumption Amongst Older Patients with High Risk AML Treated with Hypomethylating Agents Is Similar to That of Patients Receiving Induction Chemotherapy

A Phase 1/2 Study of the Oral Novel JAK1 Inhibitor INCB052793 As Monotherapy and in Combination with Standard Therapies in Patients with Advanced Hematologic Malignancies

Increased NKT-like Cells and Markers of T Cell Activation in Long Term Survivors of Allogeneic Hematopoietic Cell Transplantation

The Contribution of Toll-like Receptor (TLR) Pathway Hyper-Reactivity to Clonal Selection in Secondary MDS and AML

The Utility Of Monitoring Chimerism: More Predictive For Nonablative Regimens?

Is There a Role for ASCT in Patients with Desmoplastic Small Round Cell Tumor of the Peritoneum?

Transfusion Practices of Critical Care Physicians During Shortages

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only